BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khan N, Patel D, Pernes T, Patel M, Trivedi C, Medvedeva E, Xie D, Yang YX. The Efficacy and Safety of Switching From Originator Infliximab to Single or Double Switch Biosimilar Among a Nationwide Cohort of Inflammatory Bowel Disease Patients. Crohns Colitis 360 2021;3:otab022. [PMID: 36778941 DOI: 10.1093/crocol/otab022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Nabi H, Hendricks O, Jensen DV, Loft AG, Pedersen JK, Just SA, Danebod K, Munk HL, Kristensen S, Manilo N, Colic A, Linauskas A, Thygesen PH, Christensen LB, Kalisz MH, Lomborg N, Chrysidis S, Raun JL, Andersen M, Mehnert F, Krogh NS, Hetland ML, Glintborg B. Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry. RMD Open 2022;8:e002560. [DOI: 10.1136/rmdopen-2022-002560] [Reference Citation Analysis]
2 Allocati E, Godman B, Gobbi M, Garattini S, Banzi R. Switching Among Biosimilars: A Review of Clinical Evidence. Front Pharmacol 2022;13:917814. [DOI: 10.3389/fphar.2022.917814] [Reference Citation Analysis]
3 Macaluso FS, Cummings JF, Atreya R, Choi J, Orlando A. A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence. Expert Opin Biol Ther 2021. [PMID: 34314284 DOI: 10.1080/14712598.2021.1958778] [Cited by in F6Publishing: 1] [Reference Citation Analysis]